• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home Uncategorized

Sublingual immunotherapy may be safe and effective for asthma and allergic rhinoconjunctivitis

bys25qthea
March 27, 2013
in Uncategorized
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

[tabs tab1=”2MM Rundown” tab2= “2MM Full Report”]

[tab]

Image: PD/Pollen, a common allergen

1. Sublingual immunotherapy was shown to have high strength evidence for the use in patients with asthma, and there is moderate strength evidence for use in allergic rhinoconjunctivitis. 

2. High-quality randomized control trials are needed to answer questions of optimal dosing and length of treatment needed to show improvement of symptoms.

Sublingual immunotherapy is appealing because it is does not require injections, can be self-administered at home, and reduces the number of office visits. The use of sublingual immunotherapy to treat symptoms of asthma and allergic rhinoconjunctivitis is approved for use in Europe but not yet in the United States. This systematic review demonstrated strong evidence that the use of sublingual immunotherapy is safe and beneficial in the reduction of symptoms. As a result, this should prompt the design of randomized control trials to show if there is a difference between the uses of sublingual immunotherapy compared to our current treatment of subcutaneous immunotherapy.

While sublingual immunotherapy has shown to have moderate evidence for the treatment of asthma and allergic rhinoconjunctivitis symptoms, most studies in this review used a single allergen extract. The use of single allergen extract is in contrast to the usual presentation of patients who often have numerous unrelated allergies. Currently, sublingual immunotherapy is used “off-label” in the US using 8 or more allergen extracts. Therefore, when designing randomized control trials this information should be taken into account since multiple allergen mixes could result in a differing response.

RELATED REPORTS

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

Click to read the study in JAMA

[/tab]

[tab]

Image: PD/Pollen, a common allergen

1. Sublingual immunotherapy was shown to have high strength evidence for the use in patients with asthma, and there is moderate strength evidence for use in allergic rhinoconjunctivitis. 

2. High-quality randomized control trials are needed to answer questions of optimal dosing and length of treatment needed to show improvement of symptoms.

This [systematic review] study: This study included 63 studies with 5,131 patients ranging from 4 to 74 years. The primary outcomes included symptom and medication scores, quality of life, and safety. Secondary outcomes included pulmonary function tests and allergen challenge. Primary outcomes were graded using the GRADE guidelines. Eight of thirteen studies show strong evidence supporting the use of sublingual immunotherapy in asthma with a magnitude of association of 69% in 9 of the studies. Sublingual immunotherapy demonstrated a 40% improvement of symptoms in patients with asthma. Also, sublingual immunotherapy decreased medication use for allergies by 40% in 16 of 41 studies. Nine of 36 studies show moderate evidence for the use of sublingual immunotherapy for rhinitis or rhinoconjunctivitis. Safety outcomes included application site reactions. No anaphylactic reactions were reported. A meta-analysis could not be performed due to the heterogeneity of the studies included. Overall, this systematic review supports moderate strength evidence for the use of sublingual immunotherapy for allergic rhinoconjunctivits and asthma.

In sum: Sublingual immunotherapy is appealing because it is does not require injections, can be self-administered at home, and reduces the number of office visits. The use of sublingual immunotherapy to treat symptoms of asthma and allergic rhinoconjunctivitis is approved for use in Europe but not yet in the United States. This systematic review demonstrated strong evidence that the use of sublingual immunotherapy is safe and beneficial in the reduction of symptoms. As a result, this should prompt the design of randomized control trials to show if there is a difference between the uses of sublingual immunotherapy compared to our current treatment of subcutaneous immunotherapy.

While sublingual immunotherapy has shown to have moderate evidence for the treatment of asthma and allergic rhinoconjunctivitis symptoms, most studies in this review used a single allergen extract. The use of single allergen extract is in contrast to the usual presentation of patients who often have numerous unrelated allergies. Currently, sublingual immunotherapy is used “off-label” in the US using 8 or more allergen extracts. Therefore, when designing randomized control trials this information should be taken into account since multiple allergen mixes could result in a differing response.

Click to read the study in JAMA

By Brittany Hasty and Rif Rahman

More from this author: Sildenafil does not improve outcomes in patients with heart failure, Increased incidence of advanced breast cancer found in young women, Increasing malaria prophylaxis doses in pregnancy associated with decrease in low birth weight infants

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

[/tab]

[/tabs]

Tags: allergic rhinoconjunctivitisasthmaSublingual immunotherapy
Previous Post

A word on stats [Perspective]

Next Post

microRNA inhibitor shows promise in the treatment of Hepatitis C

RelatedReports

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Emergency

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

June 21, 2022
Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

April 5, 2022
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Chronic Disease

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

March 9, 2022
Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial
Chronic Disease

Itepekimab provides beneficial effects for patients with moderate-to-severe asthma.

November 12, 2021
Next Post
microRNA inhibitor shows promise in the treatment of Hepatitis C

microRNA inhibitor shows promise in the treatment of Hepatitis C

Rhinovirus, genes may interact to increase the risk of childhood asthma

Rhinovirus, genes may interact to increase the risk of childhood asthma

Physical therapy equal to surgery for symptomatic meniscal tears

Physical therapy equal to surgery for symptomatic meniscal tears

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous fluid restriction does not improve septic shock outcomes
  • Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients
  • Magnetic resonance based preoperative evaluation for perianal fistulas superior to traditional clinical method and improve surgical outcomes [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.